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Background. Honokiol, a small molecular weight natural product, has been shown to possess potent anti-neoplastic and anti-
angiogenic properties. Its molecular mechanisms and the ability of anti-gastric cancer remain unknown. It has been shown that
the anti-apoptotic function of the glucose-regulated proteins (GRPs) predicts that their induction in neoplastic cells can lead to
cancer progression and drug resistance. We explored the effects of honokiol on the regulation of GRPs and apoptosis in human
gastric cancer cells and tumor growth. Methodology and Principal Findings. Treatment of various human gastric cancer cells
with honokiol led to the induction of GRP94 cleavage, but did not affect GRP78. Silencing of GRP94 by small interfering RNA
(siRNA) could induce cell apoptosis. Treatment of cells with honokiol or chemotherapeutics agent etoposide enhanced the
increase in apoptosis and GRP94 degradation. The calpain activity and calpain-II (m-calpain) protein (but not calpain-I (m-
calpain)) level could also be increased by honokiol. Honokiol-induced GRP94 down-regulation and apoptosis in gastric cancer
cells could be reversed by siRNA targeting calpain-II and calpain inhibitors. Furthermore, the results of immunofluorescence
staining and immunoprecipitation revealed a specific interaction of GRP94 with calpain-II in cells following honokiol treatment.
We next observed that tumor GRP94 over-expression and tumor growth in BALB/c nude mice, which were inoculated with
human gastric cancer cells MKN45, are markedly decreased by honokiol treatment. Conclusions and Significance. These
results provide the first evidence that honokiol-induced calpain-II-mediated GRP94 cleavage causes human gastric cancer cell
apoptosis. We further suggest that honokiol may be a possible therapeutic agent to improve clinical outcome of gastric cancer.
Citation: Sheu ML, Liu SH, Lan KH (2007) Honokiol Induces Calpain-Mediated Glucose-Regulated Protein-94 Cleavage and Apoptosis in Human
Gastric Cancer Cells and Reduces Tumor Growth. PLoS ONE 2(10): e1096. doi:10.1371/journal.pone.0001096
INTRODUCTION
Gastric cancer is the second most common cause of cancer death
in the world [1]. Almost two-thirds of the cases occur in
developing countries and 42% in China alone [1,2]. The
molecular targets and mechanisms underlying poor prognosis
are not well understood. The treatment of locally advanced gastric
cancer remains a major challenge. Despite recent advances in
treatment, the clinical outcome for gastric cancer patients remains
poor. Apart from surgery, the role of adjuvant therapy remains
unproven [2,3]. Thus the need to identify potential novel
therapeutic and chemopreventive agents is obvious.
Honokiol, an active component isolated and purified from the
Magnolia officinalis, has been demonstrated to possess the effects of
anti-oxidation [4], against lipid peroxidation [5] and anti-
inflammatory in vitro and in vivo [6,7]. Honokiol has also been
shown to be a systemically available and non-toxic inhibitor of
angiogenesis [8]. The recent studies reported that honokiol
induces caspase-dependent apoptosis in B-cell chronic lymphocytic
leukemia cells and overcomes conventional drug resistance in
human multiple myeloma by induction of caspase-dependent and -
independent apoptosis [9,10]. Although a full assessment of the
clinical potential of the compounds is not yet possible, the
pharmacokinetics of honokiol has been thoroughly investigated,
revealing that honokiol is available upon clinical cancer therapy.
More natural products containing a variety of therapeutic
compounds useful in preventing the development of malignancies
continue to be discovered; however, very little is known about their
underlying mechanisms of action or their molecular target.
Glucose-regulated protein (GRP)94 is a most abundant
glycoprotein in endoplasmic reticulum (ER) and only be identified
in vertebrate. Over-expression antisense and ribozyme approaches
in tissues culture systems directly demonstrated that GRP78 and
GRP94 could protect cells against death [11–13]. The protective
function of the GRPs has also been observed in resistance to
radiation in cervical cancer [14]. The anti-apoptotic function of
the GRPs also predicts that their induction in neoplastic cells can
lead to cancer progression and drug resistance [15–18]. Patho-
logical conditions such as tumor growth and malignancy have
been suggested to correlate with cytoprotective protein GRP94
over-expression [19]. In metastatic malignancies model, a signifi-
cant efficacy of the GRP94-based gene/immunotherapy strategy
was shown when it was combined with radiation therapy [20]. The
ER plays a direct role in activating a subset of caspase during
activation of apoptosis that occurs during ER stress [21]. On the
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2+-dependent intracellular
cysteine proteases. Ubiquitously expressed calpain-I (m-calpain)
and calpain-II (m-calpain) proteases are implicated in develop-
ment of apoptosis. A recent study has shown that ubiquitous
calpains promote caspase-12 and JNK activation during ER stress-
induced apoptosis [22]. It has also been indicated that GRP94
with Ca
2+-binding and anti-apoptotic properties is a proteolytic
target of calpain during etoposide-induced apoptosis [23].
Moreover, in several experimental models of apoptosis, it has
been shown that the amino-terminal calpain inhibitory unit of
calpastatin can be cleaved by caspases, suggesting the cleavage is
essential for the regulation of calpain activity during cell death
[24–28]. Caspase-7, which is recruited to the ER in stressed cells,
may likewise cleave and activate caspase-12 [29–31]. The effects of
honokiol on the GRPs-related signaling and apoptosis still remain
unknown. In the present study, we explored the molecular
mechanisms of honokiol on human gastric cancer cell apoptosis
and tumor growth in vitro and in vivo. Unexpectedly, we found that
GRP94 undergoes specific proteolytic cleavage by calpain during
honokiol-induced apoptosis. These observations may give evi-
dences that honokiol is a possible therapeutic agent to improve
clinical outcome of gastric cancer.
RESULTS
Kinetics of GRP94 proteolytic cleavage in human
gastric cancer cell lines treated with honokiol
We firstly examined the effects of honokiol on the expressions of
GRP94 and GRP78 in various human gastric cancer cell lines.
Honokiol markedly decreases the levels of GRP94 in a dose- and
time-dependent manner, but GRP78 levels are not affected (Figs. 1
and 2). Kinetics of honokiol-induced GRP94 cleavage in various
human gastric cancer cells were shown in Fig. 2. MKN45 or
SCM-1 cells were more resistant to honokiol-induced responses
than AGS or N87 cells; the levels of GRP94 were reduced to about
50% for twice as much time. The levels of GRP78 proteins remain
unchanged in all four gastric cancer cell lines. Moreover, there are
little GRP94 protein expressions in normal mouse gastric
epithelium tissue and human endothelial cells as compared with
gastric cancer cells (Fig. 1C).
Honokiol induces GRP94 cleavage–associated
apoptotic response
As shown in Fig. 3, honokiol increased the poly(ADP-ribose)
polymerase (PARP) cleavage and DNA damage inducible gene
CHOP/GADD153 (a protein has been identified to mediate ER
stress-induced apoptosis) levels in MKN45 cells in a dose- and
time-dependent manner. Honokiol 20 and 40 M also triggered the
expressions of cleaved caspase-12 and caspase-7 (p20), which the
magnitude of increase was proportional to the timing (Fig. 3B).
Moreover, to understand whether GRP94 cleavage was involved
in the human gastric cancer cell apoptosis, apoptosis was detected in
GRP94-siRNA-transfected cells. Silencing of GRP94 by siRNA
induced cell apoptosis (Fig. 4A) and decreased GRP94 protein
expression (Fig. 4B-a). We also compared the effects of honokiol on
apoptosis and GRP94 degradation in human gastric cancer cells
with chemotherapeutics agent etoposide. The results showed that
treatment of cells with honokiol or etoposide enhanced the increase
in apoptosis (Fig. 4A) and GRP94 degradation (Fig. 4B-b). When
cells were simultaneously treated with 40 M etoposide and 20 M
honokiol, a larger increase in GRP94 degradation than they did was
shown (Fig. 4B-b); these results imply that the combining of honokiol
with other anticancer drugs may be a potential therapeutic strategy.
Calpain is required for honokiol-mediated cell
apoptosis
We next determined whether the activity of calpain (calcium-
dependent thiol proteases) would be induced by honokiol in
four gastric cancer cell lines. As shown in Fig. 5A, honokiol
20 M increased calpain activity in a time-dependent manner,
which started to increase at 15 min, and peaked at 60 min, and
then dropped down to a lower level at 4 h. Cells remained
adherent over the time course, with no loss of viability (data not
shown). In Fig. 5B, the results showed that the increase of calpain
activity in response to honokiol (20 and 40 M) for 60 min in four
gastric cancer cell lines. Furthermore, calpain inhibitors, N-
acetyl-leu-leu-norleucinal (ALLN), N-acetyl-leu-leu-methioninal
Figure 1.Effects of honokiol onthe expressions ofGRP94 and GRP78in
human gastric cancer cell lines. (A) Western blot analyses for GRP94 and
GRP78 in MKN45 cells treated with honokiol for 8 h in a dose-response
manner. (B) Western blot analyses for GRP94 and GRP78 in MKN45 cells
treated with honokiol (a, 20mM; b, 40 mM) in a time-response manner. (C)
Comparison of GRP94 protein expression among human gastric cancer
celllines(SCM-1,AGS,N87,andMKN45),tumorisolatedfromMKN45cells-
inoculated mice (T), normal mouse gastric epithelium tissue (N), and
human umbilical vein endothelial cells (HUVEC). All results shown are
representative of at least four independent experiments.
doi:10.1371/journal.pone.0001096.g001
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of calpain activity induced by honokiol in N87 and SCM-1 cells
(Fig. 5C).
We further tested whether decreased calpain activity could
compromise the ability of honokiol on apoptosis induction. As
shown in Fig. 6A, honokiol (40 M) induced cell apoptosis in
SCM-1 cell, which could be reversed by calpain inhibitors (ALLN
or ALLM). Moreover, honokiol enhanced calpain-II protein but
not calpain-I protein expressions in SCM-1 cells (Fig. 7A). Using
a siRNA approach to knockdown calpain-II activity led to
a significant abatement of honokiol (20 M)-induced apoptosis
in human gastric cancer cells after 4 h treatment (Fig. 6B).
SiRNA-calpain-I did not affect honokiol-induced apoptosis
(Fig. 6B).
Localization and interaction of calpain-II and GRP94
following honokiol treatment
The next step was to elucidate the role of calpain-II in honokiol-
induced GRP94 degradation. In laser confocal microscopic study,
the localization of calpain-II protein was determined by green
fluorescence, whereas the localization of GRP94 was determined
by red fluorescence. As shown in Fig. 7B, both calpain-II and
GRP94 were detected in cytoplasm with co-localization in human
gastric cancer cells. The fluorescence of calpain-II was gradually
increased, but fluorescence of GRP94 was gradually decreased in
human gastric cancer cells under honokiol treatment. To further
confirm the results from immunocytochemical staining that
Figure 2. Kinetics changes of GRP94 and GRP78 protein expression in various human gastric cancer cell lines following honokiol treatments.
Western blot analyses for GRP94 and GRP78 in cells (N87 (A), AGS (B), MKN45 (C) and SCM-1 (D)) treated with 40 mM honokiol for various time courses
as indicated. Data are presented as mean6SEM (n=5).
doi:10.1371/journal.pone.0001096.g002
Figure 3. Honokiol induces a GRP94 degradation-associated apoptotic
response in human gastric cancer cells. (A) Western blot analyses for
PARPandGADD153inMKN45cellstreatedwithhonokiolfor8 hinadose-
responsemanner.(B)TimecourseresponsesforPARP,GADD153,caspase-
7 and caspase-12 in MKN45 cells treated with honokiol (20 mM). Results
shown are representative of at least four independent experiments.
doi:10.1371/journal.pone.0001096.g003
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tation and Western blotting in gastric cancer cells were performed.
As shown in Fig. 7C, calpain-II was specifically associated with
GRP94 in various gastric cancer cells in the presence of honokiol
(20 and 40 M) as compared with IgG control. Moreover, we tested
whether the proteolytic activities of caspase, proteasome or
cathepsin were involved in the cleavage of GRP94. Our results
showed that treatment of cells with caspase inhibitors (Ac-DEVD-
CHO, Z-VAD-FMK and Z-DEVD-FMK, 50 M) at high dose
partially blocked the cleavage of GRP94 during honokiol-induced
apoptosis (Fig. 8A) as compared with calpain inhibitor ALLM
25 M, which could completely block GRP94 cleavage. Pre-
Figure 4. Silencing of GRP94 by siRNA induces cell apoptosis. (A) Apoptosis in GRP94-siRNA-transfected MKN45 cells was analyzed by Annexin V/PI
staining as described under Materials and Methods, which was compared with cells treated with honokiol (40 mM) or etoposide (40 mM). (B-a) GRP94
protein levels were detected by Western blot analysis in control and GRP94-siRNA-transfected MKN45 cells. (B-b) Honokiol and etoposide induce
GRP94 cleavage in MKN45 cells. Cells were treated with 20 mM honokiol and 40 mM etoposide (Etopo.) as indicated for 4 h. Results shown are
representative of at least four independent experiments.
doi:10.1371/journal.pone.0001096.g004
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and 50 M and cathepsin L inhibitor cathepsin L inhibitor II 25
and 50 M and proteasome inhibitor MG132 0.1-10 M was unable
to block GRP94 cleavage (Figs. 8B and 8C). Furthermore, the
specific cleavage of GRP94 by calpain could be observed using
cell lysates prepared from human gastric cancer cells (data not
shown).
We next investigated whether the calpain activation is required
for honokiol-induced cell apoptosis. In Fig. 9, the increases of
calpain-II protein expression and GRP94 degradation and
caspase-7 and caspase-12 activation induced by honokiol (40 M)
were prevented by pharmacological calpain inhibitors and
transient transfection of siRNA-calpain-II in SCM-1 cells.
Honokiol attenuates tumor GRP94 over-expression
and tumor growth in nude mice
Nude mice were inoculated with 4610
6 undifferentiated adenocar-
cinoma cells MKN45 and treated with honokiol 0.5 and 1.5 mg/kg
or vehicle when tumor became evident. Immunohistological and
Western blotting analysis showed that GRP94 over-expression and
accumulated in tumor region, but not in normal gastric tissue
(Figs. 10A-a and 10A-b). Honokiol markedly decreased the
accumulation of GRP94 in tumors as compared with vehicle control
(Figs. 10A-a and 10A-b). The expression of GRP78 was not affected
(data not shown). To determine whether honokiol could suppress
tumor growth in vivo, solid tumors were established in mice and the
anti-tumor effect of repeatedly injected honokiol was studied. As
showninFig.10B,theadministrationofhonokiol0.5and1.5 mg/kg
showed a significant anti-tumor activity.
DISCUSSION
We reported here for the first time that calpain, a nonlysosomal
Ca
2+-activated cysteine protease, especially calpain-II, plays a key
role in the cleavage of GRP94, but GRP78 is not affected, and in
the regulation of apoptosis induced by honokiol in human gastric
cancer cells. In particular, we provided functional evidences that
the cleavage of GRP94 upon honokiol treatment acts as
a therapeutic benefit, inhibiting tumor growth in mouse model
of human gastric carcinoma. To our knowledge, this is the first
report to show that honokiol can manipulate calpain-inducible
chaperone protein GRP94 degradation being the target during
apoptosis.
Studies from multiple laboratories pointed to the ER as a target
compartment by therapeutic agents implicated in apoptosis
execution. Cytosolic Ca
2+ has been implicated as a second
messenger of proapoptosis involved in both triggering apoptosis
and regulating caspases or calpains [32–34]. A recent study has
shown that calpain is an important mediator of resveratrol (a
natural plant polyphenol)-induced apoptosis in breast cancer [35].
They found that resveratrol can cause an increase in intracellular
Ca
2+, and activates calpain-mediated apoptosis, leading to the
degradation of plasma membrane Ca
2+-ATPase isoform 1 and
fodrin in caspase-3 deficient MCF-7 cells. Honokiol has also been
reported to induce Ca
2+ mobilization in rat cortical neurons and
human neuroblastoma SH-SY5Y cells, presumably through the
activation of phospholipase C and IP3 receptors [36]. In the
present study, we found that honokiol is capable of increasing
calpain activity and calpain-II protein expression but not calpain-I
during honokiol-induced gastric cancer cell apoptosis. Moreover,
calpain inhibitors and silencing of calpain-II by siRNA signifi-
cantly reversed the honokiol-induced apoptosis. These findings
imply that Ca
2+-triggered calpain-II activation may play a potential
role in honokiol-induced apoptosis.
GRP94/gp96 is the ER resident member of the HSP90 family.
GRP94 plays an important role in maintaining cellular homeo-
stasis. This conventional concept of GRP94 as protein folding
chaperone is updated by the discoveries that GRPs promote tumor
proliferation, metastasis, drug resistance, and immunotherapy,
which have major clinical implications in the prognosis and
treatment of cancer [3]. GRP94 has been demonstrated to be
associated with tumorigenicity in cancer cell lines, rodent tumor
models and human cancer biopsies [37–39]. This is consistent with
the findings that the induction of GRPs causes a protective
function as the survival responses to nutrient starvation, acidosis,
and hypoxia conditions, which are common in poorly vascularized
solid tumors [11,40]. It has also been appeared that most of the
GRPs in tumor cells is engaged in multi-chaperone complexes,
Figure 5. Honokiol activates calpain activity. Calpain activity was
measured with the fluorescent calpain substrate Suc-LLVY-AMC in N87,
AGS, MKN45 and SCM-1 cells. (A) Time course responses to honokiol
(20 mM) treatment. Data are expressed in terms of fold of control
conditions. (B) Honokiol (20 and 40 mM) increases calpain activity at
60 min treatment. (C) Calpain inhibitors ALLN, ALLM, and Z-Leu-Leu-
CHO; 25 and 50 mM) significantly inhibited honokiol-increased calpain
activity. Data are presented as mean6SEM (n=4).
doi:10.1371/journal.pone.0001096.g005
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tumor-derived stress proteins, GRP94, can elicit anti-tumor
immune responses, yielding a marked suppression of tumor
growth and metastasis. The activity of Hsp90 inhibitors has been
well validated in preclinical breast cancer models, both in single-
agent studies and in combination with conventional chemotherapy
[41]. Moreover, it has been suggested that GRP94 is a physiolog-
ical substrate for calpain [23]. Calpain has been demonstrated to
be activated at the ER membrane, where it interacts with GRP94,
resulting in its specific proteolytic cleavage as the cells undergo
apoptosis triggered by etoposide [23]. In current study, we found
that honokiol-induced GRP94 cleavage and apoptosis in human
gastric cancer cells can be completely reversed by calpain inhibitors
and silencingofcalpain-II by siRNA.Caspase inhibitorsat high dose
partially reversed the honokiol-induced GRP94 cleavage. Pre-
treatment of cells with the cathepsin B and L inhibitors and
proteasome inhibitor was unable to block honokiol-induced GRP94
cleavage. We also demonstrated that silencing of GRP94 by siRNA
Figure 6. Suppression of calpain activity by calpain inhibitors or c siRNA-calpain-II decreased honokiol-induced cell apoptosis. Human gastric
cancer cells were analyzed for apoptosis by Annexin V/PI staining as described under Materials and Methods. (A) SCM-1 cells were treated with
honokiol (HK, 40 mM) for 4 h in the presence or absence of calpain inhibitors (ALLN and ALLM, 50 mM). (B) AGS cells transfected with siRNA-calpain-I-
or siRNA-calpain-II were treated with honokiol (HK, 20 mM) for 4 h. Results shown are representative of at least four independent experiments.
doi:10.1371/journal.pone.0001096.g006
Honokiol and Gastric Cancer
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immunocytochemical staining and immunoprecipitation revealed
a specific interaction of GRP94 with calpain-II in gastric cancer cells
following honokiol treatment. The specific cleavage of GRP94 by
calpain could also be observed using cell lysates prepared from
human gastric cancer cells. These findings, therefore, suggest that
calpain-II-mediated GRP94 cleavage plays an important role in
honokiol-triggered gastric cancer cell apoptosis.
Calpains and caspases are two families of cysteine proteases that
they are involved in regulating pathological cell death [22,31].
These proteases share several death-related substrates including
caspases themselves, cytoskeletal proteins, Bax, and Bid [42].
Calpain-mediated proteolysis proceeds in a limited manner but
does not require a specific amino acid residue like that of caspases.
Although both calpain and caspase have been proposed to play
important roles in regulating pathological cell death, the interac-
Figure 7. Effects of honokiol on calpain-I and II protein levels and interaction of calpain and GRP94. Cells were treated with honokiol (20–60 mM)
for various time courses as indicated. (A) Calpain-I and II protein levels were detected by Western blot analysis in honokiol-treated SCM-1 cells. (B)
Primary antibodies for calpain-II and GRP94 were applied to the cells (MKN45 and SCM-1) followed by secondary antibodies coupled with FITC-
conjugated or TRITC-conjugated, respectively. Co-localization of two labeled antigens was detected as a single image when the images from both
channels were overlaid. (C) Interaction of calpain and GRP94 were detected in N87, AGS, MKN45 and SCM-1 cells. Immunoprecipitated proteins were
collected and subjected to SDS-PAGE and immunoblotting with anti-calpain-II or anti-GRP94 antibodies. Results shown are representative of at least
four independent experiments.
doi:10.1371/journal.pone.0001096.g007
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conditions are not clear. In the present study, knockdown and
pharmacological inhibitors approaches have contributed signifi-
cantly to our knowledge of calpain biology, particularly with
respect to its specific function on cell apoptosis, which is possible
that caspases 7 and 12 are downstream from calpain in mediating
honokiol-induced gastric cancer cell apoptosis.
Natural product drugs have been suggested to play a dominant
role in pharmaceutical care [43]. Natural products are one of the
important sources of potential cancer chemotherapeutic and
chemopreventive agents [43]. Honokiol has been widely used in
the traditional Chinese and Japanese medicine for several
thousand years, mainly, for the treatment of anti-thrombocytic,
anti-bacterial, anti-inflammatory, and anxiolytic effects. Previous
reports have demonstrated that honokiol is also possessing potent
anti-neoplastic and anti-angiogenic properties [6,19,38]. However,
the precise molecular mechanism of exhibited anti-tumor activity
by honokiol is not well understood. Thus, the results of this study
provide evidences for the anti-tumor activity of honokiol in gastric
cancer, and more importantly, the molecular basis for its effect.
We found that honokiol induces the activation of calpain, GRP94
cleavage, and apoptosis in human gastric cancer cells. Moreover,
after administration of honokiol in nude nice implanted with
MKN45 gastric tumor cells showed significant anti-tumor activity.
This preclinical study can serve as a framework and represents
a promising novel targeted approach. In addition, the natural
compounds have been shown to combine with conventional
cytotoxic agents may be clinical beneficial with anticancer drugs.
This advantage plus the emerging evidence of its anti-tumor
mechanisms make honokiol ongoing clinical application for being
an effective and safe anti-tumor agent.
MATERIALS AND METHODS
Cells, Culture Conditions and Reagents
Human cell lines including Caucasian gastric cancer cell lines
(AGS, a moderately-poorly differentiated adenocarcinoma cell
line, and N87, a well differentiated carcinoma cell line) and Asian
gastric cancer cell lines (MKN45 and SCM-1, the undifferentiated
adenocarcinoma cells) were obtained from cell bank in cancer
center of Taipei veterans general hospital (Taiwan). Cells were
maintained in RPMI 1640 medium containing 10% heat-
inactivated FCS (Life Technologies) and streptomycin/penicillin
(Life Technologies) in a humidified 5% CO2 atmosphere.
Honokiol was obtained from Wako Chemical Company (Japan),
and its purity was determined to be a minimum of 99% by high-
performance liquid chromatography.
Western Blot Analysis and Immunoprecipitations
Whole cell lysates were prepared as described previously [44].
Proteins were separated by pre-cast 8–20% SDS-polyacrylamide
gel electrophoresis, and then electrophoretically transferred from
the gel onto polyvinylidene difluoride membranes. After blocking,
blots were incubated with, anti-GRP94, anti-GRP78, anti-caspase
12, anti-caspase 7, anti-PARP, anti-GADD153 (Santa Cruz
Biotechnology), anti-calpain-I (m-calpain), anti-calpain-II (m-cal-
pain) (Santa Cruz Biotechnology), and anti-b actin (Sigma)
antibodies in PBS within 0.1% Tween 20 for 1 h followed by
three 10 min washes in PBS within 0.1% Tween 20. The
membranes were then incubated with horseradish peroxidase-
conjugated secondary antibodies for 60 min. In immunoprecipi-
tation, proteins (500 g) were incubated with specific antibodies and
immobilized onto protein A-Sepharose beads. Beads were washed
extensively with Bacco9s immunoprecipitative buffer, boiled, and
microcentrifuged. Input 10% of cell lysate for IP and 50 g proteins
were analyzed by Western blotting. Detection was performed with
Western blotting reagent ECL (Amersham), and chemilumines-
cence was exposed by the Kodak X-Omat films.
Calpain Activity Assays
Suc-Leu-Leu-Val-Tyr-AMC is a calpain protease substrate. Quan-
titation of 7-amino-4-methylcoumarin (AMC) fluorescence permits
the monitoring of enzyme hydrolysis of the peptide-AMC conjugate
and can be used to measure enzyme activity. Cells were prepared
and treated on 24-well Corning/Costar plates. Prior to addition of
inhibitors cells were loaded with 40 M Suc-Leu-Leu-Val-Tyr-AMC
(Biomol) and treated with honokiol for indicated timing at 37uCi n
a humidified 5% CO2 incubator. Proteolysis of the fluorescent probe
was monitored using a fluorescent plate reading system (HTS-7000
Plus Series BioAssay, Perkin Elmer) with filter settings of
360620 nm for excitation and 460620 nm for emission.
SiRNA and Transfection Assays
The siRNA duplexes specific for the inhibition of calpain-I (m-
calpain) and calpain-II (m-calpain) expressions in human cells
were obtained from Santa Cruz Biotechnology: calpain-I, catalog
no. sc-29885, a pool of 3 target-specific 20–25 nt siRNAs; calpain-
Figure 8. Effect of inhibitors of caspases, proteasome and cathepsins
on honokiol-induced GRP94 cleavage in SCM-1 cells. Cells were either
untreated or pretreated with inhibitors for 1 h followed by 40 mM
honokiol treatment for another 24 h. (A) caspase inhibitor (Z-VAD-FMK,
25 and 50 mM) or calpain inhibitor (ALLN, 25 mM); (B) cathepsin B
inhibitor (CA-074-Me, 25 and 50 mM) or cathepsin L inhibitor (cathepsin
L inhibitor II, 25 and 50 mM); (C) proteasome inhibitor (MG132, 0.1–
10 mM) or calpain inhibitor (ALLN, 25 mM). Results shown are
representative of at least four independent experiments.
doi:10.1371/journal.pone.0001096.g008
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control siRNA (catalog no. sc-37007) is a non-targeting 20–25 nt
siRNA designed as a negative control. Moreover, the siRNA
duplexes specific for the inhibition of GRP94 expression was
synthesized commercially by MWG Biotech (Germany). The sense
(top) and antisense (bottom) sequences of the GRP94 siRNA
duplex were as follows: 59-GAAGAAGCAUCUGAUUACCTT-
39;3 9-TTCUUCUUCGUAGACUAAUGG-59. As a nonspecific
control, a NC siRNA duplex with random sequences was designed
as follows: 59-AGUUCAACGAGUAUCAGCATT-39;3 9-TTU-
CAAGUUGCUCAUAGUCGU-59. The siRNAs were used at
a concentration of 100–200 nM for transient transfection of cells
with Lipofectin (Invitrogen) per well in a 6-well plate with fresh
medium. After 24 h from the initial transfection and 24–36 h
treatment, cells or cell lysates were collected and analyzed for
apoptosis or protein expression, respectively.
Immunofluorescence and Laser Scanning Confocal
Microscopy
Cells were washed twice with PBS, fixed in 4% paraformaldehyde
for 30 min and then blocked by incubation in 1% bovine serum
albumin in PBS. Primary antibodies as indicated were applied to
the slides at a dilution of 1:500 and incubated at 4uC overnight.
The samples were treated with FITC-conjugated or TRITC-
conjugated secondary antibodies (Sigma). The FITC-labeled or
TRITC-labeled cells were then analyzed by fluorescence microsco-
py. For laser scan microscopy, immunofluorescence-labeled cells
were analyzed using an inverted laser scanning microscope (Zeiss
LSM 410 invert, Germany), equipped with both argon ion (488 nm)
and HeNe (543 nm) lasers. Co-localization of two labeled antigens
was detected as a single image when the images from both channels
were overlaid. Confocal images were background-subtracted and
merged using the Confocal Assistant software program, and
processed with Adobe Photoshop software.
Annexin-V FITC and PI Double Staining
The annexin V/propidium iodide (BD Clontech) was used to
quantify numbers of apoptotic cells as described previously [44].
Cells were washed twice with PBS and stained with annexin V and
PI for 20 min at room temperature. The level of apoptosis was
determined by measuring the fluorescence of the cells by flow
cytometer (Becton Dickinson). Data acquisition and analysis were
performed by the CellQuest program (Becton Dickinson).
Animals
Animal experiments were carried out according to the guidelines
issued by the Committee of Animal Experiments, National Chung
Hsing University, Taichung, Taiwan. Male BALB/c nude mice
(nu/nu) were purchased from NLAC Taiwan, Inc., Taipei,
Taiwan. The mice were bred and maintained under specific
pathogen–free conditions, provided with sterilized food and water
ad libitum, and housed in a barrier facility with 12 h light/dark
Figure 9. Honokiol induces calpain-mediated GRP94 degradation and apoptosis. Western blotting for determination of GRP94 degradation and
calpain-I and II expression and activation of caspase-7 and caspase-12 in SCM-1 cells 24 h after honokiol (40 mM) treatment in the presence or
absence of calpain inhibitors (ALLN and ALLM, 25 and 50 mM) was detected. In some experiments, SCM-1 cells were transfected with calpain-II-siRNA
or control-siRNA. Results shown are representative of at least four independent experiments.
doi:10.1371/journal.pone.0001096.g009
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The animals were euthanized when they appeared moribund.
Tumor Growth Assay
Celltumorigenicity was examined in6-week-old maleBALB/cnude
mice. Briefly, 4610
6 of cells (MKN45) in an exponential growth
phaseweresuspendedin1 mlculturemediumwith10%fetalbovine
serum. A single-cell suspension of MKN45 was subcutaneously
inoculated into the dorsal side of the mice. Tumors were established
for14daysafterMKN45cellsinoculationandfollowedbytreatment
with vehicle, 0.5 and 1.5 mg/kg honokiol every day for 10 days
(7 mice/group). The volume of the implanted tumor in dorsal side of
mice was measured twice a week with a caliper, using the formula
V=(LW
2) p/6: where V,v o l u m e( m m
3); L, biggest diameter (mm);
W, smallest diameter (mm).
Immunohistochemistry
The expression of GRP94 in mouse solid tumor was examined
by immunohistochemistry. Thin tumor sections (5 mm)
were prepared, fixed with cold acetone, blocked with 3%
hydrogen peroxidase, and stained with for primary GRP94
antibody.
Figure 10. Honokiol reduces tumor GRP94 over-expression and tumor growth. Tumors in nude mice were established for 14 days after MKN45
cells injection and followed by treatment with 0.5 and 1.5 mg/kg honokiol every day for 10 days. (A-a) GRP94 expressions in tumors or normal gastric
tissues were determined by immunohistochemistry. The sections were stained with GRP94 antibody as described under Materials and Methods. The
expressions of GRP94 proteins in cytoplasm were stained into dark brown. (A-b) Western blotting for determination of GRP94 proteins in tumors with
or without honokiol treatment was detected. (A-c) The detection of GRP94 protein expression by Western blotting in MKN45 cells with or without
honokiol (40 mM) treatment or in normal gastric tissues was shown. Results shown are representative of at least four independent experiments. (B)
Tumor volume was assessed. Data are presented as mean6SEM (n=7).
doi:10.1371/journal.pone.0001096.g010
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The values given in this study are presented as mean6SEM. All
analyses were performed by analysis of variance followed by
a Fisher’s least significant difference test. P value of less than 0.05
was viewed as statistical significance.
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